Media release

Ypsomed and smartpatient partner to connect smart injection devices with digital patient support

Burgdorf / Munich, 15.10.2026, 7 a.m. – Ypsomed (SIX: YPSN) and smartpatient, part of Redcare Pharmacy and provider of the MyTherapy digital patient engagement platform, are collaborating to connect Ypsomed's SmartPilot technology with MyTherapy. The collaboration brings together two parts of the treatment journey for chronic conditions that have traditionally been addressed separately: the moment of drug administration and the ongoing support patients need between injections.

SmartPilot is a reusable add-on that transforms Ypsomed's YpsoMate autoinjector into a connected drug delivery system, enabling injection-related information to be captured digitally. Through the integration with MyTherapy, this information becomes part of a broader digital patient journey. This connects drug administration with therapy-specific education, medication management and ongoing patient support.

For pharmaceutical companies, the collaboration is designed to facilitate the integration of self-injection data into established digital patient support programs without the need to build a standalone digital ecosystem for each product.

From connected injection to connected therapy

Together, SmartPilot and MyTherapy enable pharmaceutical companies to build digital experiences that connect reliable injection-related information with the support patients receive throughout their therapy journey. This includes injection guidance, medication reminders, therapy education, and personalized support based on injection-related information throughout treatment, such as additional training or tailored educational content when needed.

"Connected self-injection provides valuable insights into how patients interact with their treatment. With SmartPilot, we can add digital connectivity to the injection device. Together with smartpatient, we are creating a scalable solution that enables better support for patients throughout their treatment journey," said Florian Kühni, Head of Product Area Digital Health at Ypsomed.

"Our ambition is to make connected therapies part of a broader patient experience rather than another isolated digital solution. Ypsomed brings deep expertise at the point of drug administration, while MyTherapy provides the digital layer for continuous patient engagement. Our partnership offers pharmaceutical partners a scalable way to connect the two worlds," said Sebastian Seibold, Head of Partnerships & Growth at smartpatient.

Building a scalable ecosystem for connected therapies

The collaboration builds on both companies' experience and track record working with pharmaceutical and biotechnology companies. Ypsomed develops and manufactures self-injection systems for customers globally. smartpatient develops direct-to-patient solutions through MyTherapy across multiple therapeutic areas and markets.

The integration of SmartPilot into the MyTherapy ecosystem is designed to support different pharmaceutical products and patient needs. The connected device and digital patient support program work together to guide patients from injection to everyday therapy management. The first implementations are already in development, with further details to be announced as the collaboration progresses.

Contact
Michelle Roth, Head of Corporate Communications, Ypsomed Holding AG
+41 79 643 65 45, michelle.roth@ypsomed.com

Danielle Bullock, Head of B2B Marketing, smartpatient
+49 89 12 22 493 00, press@smartpatient.eu

smartpatient
smartpatient, part of Redcare Pharmacy, is the leading provider of direct-to-patient solutions for the pharmaceutical industry. Through MyTherapy, the world's most widely used medication management app, smartpatient helps pharmaceutical partners reduce time to treatment, extend time on treatment, and generate longitudinal real-world evidence on treatment impact. Its integrated ecosystem connects ongoing patient support, telehealth, and e-pharmacy services across the treatment journey. To learn more visit, www.smartpatient.eu.

Ypsomed Group
Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier.

Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
www.ypsomed.com